References
- 1. Rosenberg H.F.,Dyer K.D.,Foster P.S. Eosinophils: changing perspectives in health and Disease. Nat Rev Immunol. 2013 Jan;13(1):9-22.
- 2. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008 May;38(5):709-50.
- 3. Jacobsen EA,Richard A. Helmers2, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012 Nov 8;120(19):3882-90.
- 4. Horny HP, Sotlar K, Valent P. Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. Journal of Hematopathology. 2011;4(2):101-111.
- 5. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun;133(5):468-92.
- 6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.
- 7. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophilic disorders. Blood Rev. 2009 Jul;23(4):157-65.
- 8. Chusid MJ, Dale CD, West BC, Wolff SM .The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975 Jan;54(1):1-27.
- 9. Park YJ, Oh EJ, Park JW, Kim M, Han K. Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. Ann Clin Lab Sci. 2006;36(3):262-6.
- 10. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999 Sep;29(9):1172-86.
- 11. Davies L, Gather U. The Identification of Multiple Outliers. Journal of the American Statistical Association. 1993 Sep;88(423):782-92.
- 12. Rousseeuw PJ, Croux C. Alternatives to the Median Absolute Deviation. Journal of the American Statistical Association. 1993 Sep;88(424):173-83.
- 13. Mizera I, Muller CH. Location-Scale Depth. Journal of the American Statistical Association. 2004 Dec;99(468):949-89.
- 14. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol. 2010 Mar;17(2):117-24.
- 15. Liso V., Troccoli G., Specchia G. and Magno M. Cytochemical “normal” and “abnormal” eosinophils in acute leukemias. Am J Hematol. 1977;2(2): 123-31.
- 16. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol. 2009 Jan;9(1): 9-13.
- 17. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999 Mar 1;93(5):1651-7.
- 18. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14.
- 19. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007 Aug 10;25(23): 3503-10.
- 20. Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin K, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003 May 1;101(9):3386-90.
- 21. Roufosse F, Garaud S, de Leval L. Lymphoproliferative Disorders Associated With Hypereosinophilia. Semin Hematol. 2012 Apr;49(2):138-48.
- 22. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000 Feb 15;95(4):1207-13.
- 23. Stanelle J, Doring C, Hansmann ML, Kuppers R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells. Blood. 2010 Nov 18;116(20):4202-11.
- 24. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011 Feb; 12(2):151-9.
- 25. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007 Apr 1;178(7):4222-9.
- 26. Cormier S, Taranova A, Bedient C, Nguyen T, Protheroe C, Pero R et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006 Jun; 79(6):1131-9.